News headlines about Stryker Corporation (NYSE:SYK) have trended positive on Tuesday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stryker Corporation earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned media coverage about the medical technology company an impact score of 82 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern’s scoring:
- Analysts: Stryker might not be the only bidder for Novadaq (massdevice.com)
- Wall Street’s M&A Chatter From June 19: CareerBuilder, EQT-Rice Energy, Novadaq-Stryker (feeds.benzinga.com)
- Stryker Co. (SYK) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Apple, PerkinElmer rise; EQT, Seattle Genetics fall (marketbeat.com)
- Oppenheimer Holdings, Inc. Reiterates “Hold” Rating for Stryker Co. (SYK) (americanbankingnews.com)
Several research firms recently weighed in on SYK. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Stryker Corporation in a research report on Monday. BidaskClub lowered Stryker Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Citigroup Inc. boosted their target price on Stryker Corporation from $114.00 to $125.00 and gave the stock a “sell” rating in a report on Friday, June 9th. BMO Capital Markets reissued a “hold” rating and issued a $125.00 target price on shares of Stryker Corporation in a report on Tuesday, April 11th. Finally, Barclays PLC reissued a “sell” rating and issued a $133.00 target price on shares of Stryker Corporation in a report on Thursday, April 27th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company. Stryker Corporation currently has an average rating of “Hold” and an average target price of $134.29.
Shares of Stryker Corporation (NYSE SYK) traded down 0.28% during mid-day trading on Tuesday, reaching $140.98. The company’s stock had a trading volume of 1,053,608 shares. The firm’s 50-day moving average price is $139.10 and its 200 day moving average price is $129.17. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $145.62. The firm has a market cap of $52.69 billion, a P/E ratio of 31.68 and a beta of 0.81.
Stryker Corporation (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.33%. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.24 EPS. On average, analysts expect that Stryker Corporation will post $6.43 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be issued a $0.425 dividend. The ex-dividend date is Wednesday, June 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.21%. Stryker Corporation’s dividend payout ratio (DPR) is presently 38.20%.
In related news, insider David Floyd sold 7,381 shares of Stryker Corporation stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $144.70, for a total value of $1,068,030.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Timothy J. Scannell sold 13,322 shares of Stryker Corporation stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $135.89, for a total value of $1,810,326.58. The disclosure for this sale can be found here. Insiders own 7.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/06/20/favorable-press-coverage-very-likely-to-affect-stryker-corporation-syk-stock-price-updated.html.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.